01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
23:02 , Dec 27, 2018 |  BC Extra  |  Company News

China’s NMPA approves Innovent’s PD-1 mAb Tyvyt for Hodgkin lymphoma

China's National Medical Products Administration approved anti-PD-1 mAb Tyvyt sintilimab (IBI308) from Innovent Biologics Inc. (HKSE:1801) to treat relapsed or refractory classical Hodgkin lymphoma. Tyvyt brings the country's slate of approved PD-1 inhibitors to at...
00:22 , Dec 22, 2018 |  BioCentury  |  Finance

Venture surge

Venture capital investments in the life sciences surged to more than $20 billion worldwide in 2018, with VCs increasingly concentrating their disbursements in nine-digit megarounds, some of which preceded IPOs later in the year. Through...
21:31 , Dec 21, 2018 |  BioCentury  |  Product Development

China’s clinical talent gap

While regulatory changes in China have helped clear the way for rapid growth of its clinical trial infrastructure, the country’s dearth of clinical experts could hold back the expansion until new talent is up to...
20:45 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

China approves Junshi’s Tuoyi, first domestic anti-PD-1 mAb

China's National Medical Products Administration (NMPA) conditionally approved on Dec. 17 the first domestic anti-PD-1 mAb, Tuoyi toripalimab (JS001) from Shanghai Junshi Biosciences Co. Ltd. (Shanghai, China), as second-line treatment of melanoma. The news comes...
20:43 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

EMA's CHMP recommended a basket of approvals and label extensions on Dec. 14, including Orphan Drug Besremi ropeginterferon alfa-2b to treat polycythemia vera and a pair of treatments from Shionogi & Co. Ltd. (Tokyo:4507). The...
19:28 , Dec 21, 2018 |  BC Week In Review  |  Company News

Innovent diversifies pipeline with China rights to three Incyte compounds

Innovent Biologics Inc. (HKSE:1801) added three targets and a new modality to its pipeline following a deal for Chinese rights to three clinical cancer compounds from Incyte Corp. (NASDAQ:INCY). The biotech will get rights in...
23:39 , Dec 17, 2018 |  BC Extra  |  Company News

Innovent diversifies pipeline with China rights to three Incyte compounds

Innovent Biologics Inc. (HKSE:1801) added three targets and a new modality to its pipeline following a deal for Chinese rights to three clinical cancer compounds from Incyte Corp. (NASDAQ:INCY). The biotech will get rights in...